ConductScience.org, home

Gene · 6240

RRM1: ribonucleotide reductase catalytic subunit M1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. RRM1: ribonucleotide reductase catalytic subunit M1. Genes, record 6240. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6240

On this page

Gene

Symbol
RRM1
HGNC
Name
ribonucleotide reductase catalytic subunit M1
HGNC
NCBI Gene ID
6240
NCBI Gene
HGNC ID
HGNC:10451
HGNC
Ensembl
ENSG00000167325
NCBI Gene
Aliases
PEOB6, R1, RIR1, RR1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
P23921Ribonucleoside-diphosphate reductase large subunit79212Ensembl, GeneID, HGNC

Source UniProt

Patents42

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
JP 2026004568 A2026-01-1461933P23921Espacenet
US 12208133 B22025-01-282P23921Espacenet
US 11446398 B22022-09-2073864P23921Espacenet
JP 2022524081 A2022-04-27176835P23921Espacenet
US 11078247 B22021-08-039823P23921Espacenet
JP 2019054813 A2019-04-11242368P23921Espacenet
JP 2018138044 A2018-09-06145P23921Espacenet
US 10046010 B22018-08-14145P23921Espacenet
EP 3258268 A12017-12-20193P23921Espacenet
JP 2017121241 A2017-07-13242368P23921Espacenet

1 to 10 of 42

See all 42 patents

Drugs10

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
CLOFARABINECHEMBL1750Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
FLUDARABINE PHOSPHATECHEMBL1096882Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GALLIUM NITRATECHEMBL1200983Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GEMCITABINECHEMBL888Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
GEMCITABINE HYDROCHLORIDECHEMBL1637Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
HYDROXYUREACHEMBL467Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
MOTEXAFIN GADOLINIUMCHEMBL3544910Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TEZACITABINECHEMBL3989496Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TEZACITABINE ANHYDROUSCHEMBL2105467Ribonucleoside-diphosphate reductase RR1 inhibitorINHIBITORChEMBL
TRIAPINECHEMBL231616Ribonucleotide reductase inhibitorINHIBITORChEMBL

Trials3,175

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07604766GEMCITABINEPHASE3ClinicalTrials.gov
NCT07603557FLUDARABINE PHOSPHATEPHASE2ClinicalTrials.gov
NCT07602140GEMCITABINEPHASE2ClinicalTrials.gov
NCT07598318GEMCITABINEPHASE2/PHASE3ClinicalTrials.gov
NCT07579195GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07575191GEMCITABINEPHASE1/PHASE2ClinicalTrials.gov
NCT07570849GEMCITABINEPHASE2ClinicalTrials.gov
NCT07570823GEMCITABINEPHASE3ClinicalTrials.gov
NCT07570017GEMCITABINEPHASE1ClinicalTrials.gov
NCT07569679GEMCITABINEPHASE2ClinicalTrials.gov

1 to 10 of 3,175

See all 3,175 trials

NIH grants1,758

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleRRM1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant222025
P30CA008748Cancer Center Support Grant132025
P01CA013106Targeting Transcription and Splicing in Cancer112025
P30CA022453CANCER CENTER SUPPORT GRANT112025
P30CA033572Cancer Center Support Grant102025
R01GM070503Molecular Recognition During Pre-mRNA Splicing102025
P30CA086862Cancer Center Support Grant92025
ZIAAG000511Post-transcriptional control of Proliferation, Stress Response & Carcinogenesis82025
P30CA043703Case Comprehensive Cancer Center Support Grant72025
P30CA093373Cancer Center Support Grant P3062025

1 to 10 of 1,758Source NIH's project files

See all 1,758 nih grants

Papers3,003

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Conformational plasticity and sequence specificity interplay in noncanonical tandem RRM-RNA binding.Biophys J202642740374PubTator, text miningPubMed
Astrocyte-microglia lactate shuttle restrains microglial phenotypic transition during myelin phagocytosis in radiation-induced brain injury.Neurooncol Adv202642699581PubTator, text miningPubMed
Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non-Small Cell Lung Cancer.Cancer Res Commun202642664521PubTator, text miningPubMed
A prognostic lncRNA signature associated with ribonucleotide reductase predicts overall survival and immune landscape in hepatocellular carcinoma.Front Cell Dev Biol202642661875PubTator, text miningPubMed
EF-P-Mediated Enhancement of Protein Synthesis: Cyclic Dipeptide Incorporation Using Mono- and Bisaminoacylated tRNAs.ACS Chem Biol202642617067PubTator, text miningPubMed
Molecular Docking and Pharmacological In Silico Evaluation of Genistein and Hematoxylin as Promising Ribonucleotide Reductase-targeted Therapies for Cancer.Curr Comput Aided Drug Des202642576557PubTator, text miningPubMed
Ensemble Docking and Molecular Dynamics Indicate Dynamic Modulation of hnRNPA1 UP1 Interdomain Behavior by Natural Products.ACS Omega202642495344PubTator, text miningPubMed
3D epigenomic remodelling mediated by Foxa1 drives gemcitabine resistance in pancreatic cancer.Cancer Lett202642457018PubTator, text miningPubMed
Metabolic and Molecular Mechanisms of Gemcitabine Resistance in Urothelial Carcinoma.Cancers (Basel)202642449668PubTator, text miningPubMed
Chk1 inhibition emerges as the most effective partner for PARP inhibition in BRCA-proficient pancreatic cancer.Discov Oncol202642446852PubTator, text miningPubMed

1 to 10 of 3,003

See all 3,003 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/6240

GET https://conductscience.org/api/genes/v1/6240/patents?page=2